COMMENTARY: The MMRpro model accurately predicted the probability of carrying a cancer-susceptibility gene mutation for the Lynch syndrome
- CITATIONS AND CLINICIANS' NOTES: BIOLOGY -- DISEASE. // Current Medical Literature: Breast Cancer;2004, Vol. 16 Issue 4, p83
Discusses several studies on cancer. Impact of comorbidity on the treatment and complications of breast cancer; Diagnosis of breast cancer in young women; Epidermal growth factor receptor mutations in lung cancer.
- Prevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer. Peto, Julian; Collins, Nadine; Barfoot, Rita; Seal, Sheila; Warren, William; Rahman, Nazneen; Easton, Douglas F.; Evans, Christopher; Deacon, Judith; Stratton, Michael R. // JNCI: Journal of the National Cancer Institute;06/02/99, Vol. 91 Issue 11, p943
Presents information on a study which examined patients with early-onset breast cancer from Great Britain for mutations in both BRCA1 and BRCA2 genes. Patients and methods; Results and discussion; Implications of results.
- Response. Narod, Steven // JNCI: Journal of the National Cancer Institute;Apr2014, Vol. 106 Issue 4, p1
A letter to the editor is presented related to increased death ratio of 1.8 in patients with ovarian cancer due to mutations in PPM1D gene in a previous issue.
- The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Vazina, A; Baniel, J; Yaacobi, Y; Shtriker, A; Engelstein, D; Leibovitz, I; Zehavi, M; Sidi, A A; Ramon, Y; Tischler, T; Livne, P M; Friedman, E // British Journal of Cancer;8/15/2000, Vol. 83 Issue 4, p463
Inherited predisposition occurs in 5-10% of all prostate cancer (CaP) patients, but the genes involved in conferring genetic susceptibility remain largely unknown. Several lines of evidence indicate that germline mutations inBRCA1 andBRCA2 might be associated with an increased risk for CaP....
- Ovarian cancer patients survive longer with BRCA2 mutated in tumors. // Biomedical Market Newsletter;10/17/2011, Vol. 21, p858
The article discusses the impact of BRAC2 genetic mutations in tumors on women with ovarian cancer that helps patients to live longer and respond better to chemotherapy.
- HFE Gene Mutation, Chronic Liver Disease, and Iron Overload In Turkey. Oya YÃ¶nal; Ãzden HatÄ±rnaz; Filiz AkyÃ¼z; Ugur Ãzbek; Kadir Demir; Sabahattin Kaymakoglu; Atilla Ãkten // Digestive Diseases & Sciences;Nov2007, Vol. 52 Issue 11, p3298
AbstractÃ‚Â Ã‚Â We aimed to determine the relationships between iron overload and HFE gene mutation in chronic liver disease in Turkey. One hundred thirteen chronic liver disease patients and 138 healthy controls were evaluated regarding their clinical, biochemical, and genetic...
- Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission. Zampino, Rosa; Marrone, Aldo; Karayiannis, Peter; Cirillo, Grazia; Miraglia del Giudice, Emanuele; Rania, Giovanni; Utili, Riccardo; Ruggiero, Giuseppe // American Journal of Gastroenterology;Sep2002, Vol. 97 Issue 9, p2426
OBJECTIVES:In this study, we aimed to evaluate the persistence of hepatitis B virus (HBV) DNA and the role of HBV core promoter and precore region mutations in 28 young cancer survivor patients with HBV or HBV and hepatitis C virus (HCV) infections, and persistently normal ALT levels, after...
- VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. Emma R. Woodward; Kerry Wall; Joan Forsyth; Fiona Macdonald; Eamonn R. Maher // Brain: A Journal of Neurology;Mar2007, Vol. 130 Issue 3, p836
Haemangioblastomas of the CNS are a cardinal feature of von Hippelâ€“Lindau (VHL) disease, a dominantly inherited multisystem familial cancer syndrome caused by germline mutation of the VHL tumour suppressor gene. We investigated the frequency of VHL mutations in 188 patients presenting...
- Association of Poor Prognosis With Loss of 12q, 17p, and 18q, and Concordant Loss of 6q/17p and 12q/18q in Human Pancreatic Ductal Adenocarcinoma. Yatsuoka, Toshimasa; Sunamura, Makoto; Furukawa, Toru; Fukushige, Shinichi; Yokoyama, Tadaaki; Inoue, Hiroko; Shibuya, Kazuhiko; Takeda, Kazunori; Malsuno, Seiki; Horii, Akira // American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p2080
OBJECTIVE: Pancreatic cancer is one of the diseases with the poorest prognosis, but the associated genetic alterations are not yet well understood. The genetic alterations reported to date in pancreatic cancer include frequent mutations of the KRAS, TP53, p16, and SMAD4 genes....